End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.50 THB | -2.50% |
|
-4.41% | -25.71% |
Summary: Com7
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Com7
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.63 for the 2025 fiscal year.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses: Com7
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings Chart: Com7
Source: Surperformance
Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
---|---|---|---|---|---|
1.44B | |||||
525M | |||||
- | - | 69.06M | |||
Average | 677.09M | ||||
Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
-
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- COM7 Stock
- Ratings Com7
Select your edition
All financial news and data tailored to specific country editions